Leo I. Gordon, MD, on Hodgkin Lymphoma: Management Strategies

2017 NCCN Annual Conference

Leo I. Gordon, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses novel immunomodulatory agents and standard treatment options for patients with relapsed or refractory Hodgkin lymphoma.

Margaret A. Tempero, MD, on Pancreatic Cancer: Active Systemic Treatment

Margaret A. Tempero, MD, of the UCSF Helen Di...

Head and Neck Cancer

David G. Pfister, MD, on HPV and Head and Neck Cancer

David G. Pfister, MD, of Memorial Sloan Kette...

Bladder Cancer

Elizabeth R. Plimack, MD, on Bladder Cancer: Management Updates

Elizabeth R. Plimack, MD, of Fox Chase Cancer...

Gynecologic Cancers

ASCO Post

Christina S. Chu, MD, on HPV and Cervical/Vulvar Cancer

Christina S. Chu, MD, of Fox Chase Cancer Cen...

Hematologic Malignancies

Ruben A. Mesa, MD, on Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines

Ruben A. Mesa, MD, of the Mayo Clinic Cancer ...

Feb

Today In Oncology

Leo I. Gordon, MD, on Hodgkin Lymphoma: Management Strategies

Related Videos

Margaret A. Tempero, MD, on Pancreatic Cancer: Active Systemic Treatment

David G. Pfister, MD, on HPV and Head and Neck Cancer

Elizabeth R. Plimack, MD, on Bladder Cancer: Management Updates

Christina S. Chu, MD, on HPV and Cervical/Vulvar Cancer

Ruben A. Mesa, MD, on Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines

Talazoparib for Pretreated Patients With Metastatic Castration-Resistant Prostate Cancer

HSD3B1 Genotype and Its Effect on Castration Resistance and Overall Survival in Prostate Cancer

IASLC Early Lung Imaging Confederation Initiative for Analysis of Low-Dose CT Images

Osimertinib Plus Savolitinib for EGFR-Mutated, MET-Amplified NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors

PROs With Addition of Pembrolizumab vs Placebo to Pemetrexed and Platinum for Nonsquamous NSCLC